Categories News Press Releases Archives 2025 July June May April March February January 2024 December November October September August July June May April March February January 2023 December November October September August July June April March February January 2022 December November October September August June May March February January 2021 December November October September August May April February Oct 12 Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa Read More Share:| | | Mar 18 Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks Read More Share:| | | Pagination First page Previous page ‹ Previous Page 1 Current page 2